News & Media
Jan 20 / 2025
Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Hemostemix Presents at Puerto Rico Investor Summits: Showcasing Global Scale-Up Strategy and Economic Impact
Jan 06 / 2025
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% reimbursement of R&D expenses in cash
Hemostemix Announces the Incorporation of Hemostemix PR Inc: 50% reimbursement of R&D expenses in cash
Dec 31 / 2024
Hemostemix’s social media Awareness of “Your Fountain of Youth” (TM) Regenerative Medicine Treatments is gaining traction
Hemostemix’s social media Awareness of “Your Fountain of Youth” (TM) Regenerative Medicine Treatments is gaining traction
Nov 28 / 2024
Hemostemix ANNOUNCES $2,675,981 Private Placement including second tranche of $833,258
Hemostemix ANNOUNCES $2,675,981 Private Placement including second tranche of $833,258
Nov 25 / 2024
Hemostemix ANNOUNCES ACP-01 Treatment-Purchase available with Social Media campaign underway
Hemostemix ANNOUNCES ACP-01 Treatment-Purchase available with Social Media campaign underway
Oct 31 / 2024
Hemostemix ANNOUNCES the first tranche closing of $1.8M of its recently announced Private Placement
Hemostemix ANNOUNCES the first tranche closing of $1.8M of its recently announced Private Placement
Aug 01 / 2024
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01
Jun 03 / 2024
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Oct 30 / 2023
Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Aug 29 / 2023
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
May 02 / 2023
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
Apr 03 / 2023
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates
Jan 23 / 2023
Hemostemix Hiring 4 New Biotechnologists in Montreal and Applying for Grants to Fund up to 75% of 5-Year Costs
Hemostemix Hiring 4 New Biotechnologists in Montreal and Applying for Grants to Fund up to 75% of 5-Year Costs